PL4143179T3 - Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworu - Google Patents
Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworuInfo
- Publication number
- PL4143179T3 PL4143179T3 PL21722227.2T PL21722227T PL4143179T3 PL 4143179 T3 PL4143179 T3 PL 4143179T3 PL 21722227 T PL21722227 T PL 21722227T PL 4143179 T3 PL4143179 T3 PL 4143179T3
- Authority
- PL
- Poland
- Prior art keywords
- ylmethanol
- azetidin
- cancer
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020062103 | 2020-04-30 | ||
| PCT/EP2021/061401 WO2021219849A1 (en) | 2020-04-30 | 2021-04-30 | Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4143179T3 true PL4143179T3 (pl) | 2026-03-23 |
Family
ID=75728860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21722227.2T PL4143179T3 (pl) | 2020-04-30 | 2021-04-30 | Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworu |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230174514A1 (pl) |
| EP (1) | EP4143179B1 (pl) |
| JP (1) | JP7789693B2 (pl) |
| KR (1) | KR20230005938A (pl) |
| CN (1) | CN115551841A (pl) |
| AR (1) | AR121982A1 (pl) |
| AU (1) | AU2021266148A1 (pl) |
| BR (1) | BR112022021976A2 (pl) |
| CA (1) | CA3177335A1 (pl) |
| ES (1) | ES3055903T3 (pl) |
| HR (1) | HRP20251578T1 (pl) |
| IL (1) | IL297675B1 (pl) |
| MA (1) | MA59447B1 (pl) |
| PH (1) | PH12022500015A1 (pl) |
| PL (1) | PL4143179T3 (pl) |
| RS (1) | RS67648B1 (pl) |
| TW (1) | TWI904157B (pl) |
| UA (1) | UA130467C2 (pl) |
| WO (1) | WO2021219849A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| EP4423082A1 (en) | 2021-10-26 | 2024-09-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| KR20240090693A (ko) * | 2021-10-28 | 2024-06-21 | 이도르시아 파마슈티컬스 리미티드 | Ccr6 수용체 조절인자 |
| WO2024121138A1 (en) | 2022-12-06 | 2024-06-13 | Idorsia Pharmaceuticals Ltd | Crystalline adipic acid salt form of a ccr6 antagonist |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US28141A (en) | 1860-05-08 | Stephen l | ||
| US3479370A (en) | 1966-08-08 | 1969-11-18 | Robins Co Inc A H | Esters of 1-substituted-3-disubstituted-pyrrolidinemethanols |
| US3489769A (en) | 1968-06-20 | 1970-01-13 | Robins Co Inc A H | 1-substituted-3-aroyl-pyrrolidines |
| US3499002A (en) | 1968-06-20 | 1970-03-03 | Robins Co Inc A H | 1-carbamoyl-3-aroylpyrrolidines |
| US3542807A (en) | 1969-04-14 | 1970-11-24 | Robins Co Inc A H | 1-(omega-benzoylalkyl)-3-substituted pyrrolidines |
| US3651085A (en) | 1969-04-14 | 1972-03-21 | Robins Co Inc A H | 1-(omega-benzoylalkyl)-3-substituted pyrrolidines |
| US3694458A (en) | 1970-08-31 | 1972-09-26 | Robins Co Inc A H | 1-nitrosopyrrolidines |
| US5278045A (en) | 1990-02-28 | 1994-01-11 | Du Pont Merck Pharmaceutical Company | Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function |
| ATE140224T1 (de) * | 1992-03-27 | 1996-07-15 | Schering Corp | Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung |
| FR2775477B1 (fr) | 1998-02-27 | 2000-05-19 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique |
| DE10144872A1 (de) * | 2001-09-12 | 2003-03-27 | Bayer Cropscience Gmbh | Azetidinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| WO2007022351A2 (en) | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| ES2554646T3 (es) | 2007-02-23 | 2015-12-22 | Theravance Biopharma R&D Ip, Llc | Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos |
| WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| CN103588697B (zh) | 2012-08-14 | 2017-09-15 | 中国科学院上海药物研究所 | 一类2，5‑二取代苯磺酰胺类化合物及其制备方法和用途 |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| CN103800309A (zh) | 2012-11-15 | 2014-05-21 | 中国科学院上海药物研究所 | 金精三羧酸在制备靶向趋化因子受体的药物中的用途 |
| ES2742843T3 (es) | 2013-10-15 | 2020-02-17 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo de ROR(gamma)t |
| KR20160068957A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | Ror-gamma-t의 메틸렌 결합 퀴놀리닐 조절제 |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| JP2020530848A (ja) | 2017-08-14 | 2020-10-29 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用 |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| CN111971279B (zh) | 2018-01-26 | 2025-09-09 | 拉普特医疗公司 | 趋化因子受体调节剂及其用途 |
| GEP20237476B (en) | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
-
2021
- 2021-04-30 BR BR112022021976A patent/BR112022021976A2/pt unknown
- 2021-04-30 ES ES21722227T patent/ES3055903T3/es active Active
- 2021-04-30 RS RS20260057A patent/RS67648B1/sr unknown
- 2021-04-30 KR KR1020227042002A patent/KR20230005938A/ko active Pending
- 2021-04-30 CN CN202180031855.9A patent/CN115551841A/zh active Pending
- 2021-04-30 TW TW110115784A patent/TWI904157B/zh active
- 2021-04-30 US US17/997,531 patent/US20230174514A1/en active Pending
- 2021-04-30 PH PH1/2022/500015A patent/PH12022500015A1/en unknown
- 2021-04-30 MA MA59447A patent/MA59447B1/fr unknown
- 2021-04-30 UA UAA202204500A patent/UA130467C2/uk unknown
- 2021-04-30 WO PCT/EP2021/061401 patent/WO2021219849A1/en not_active Ceased
- 2021-04-30 AR ARP210101183A patent/AR121982A1/es unknown
- 2021-04-30 EP EP21722227.2A patent/EP4143179B1/en active Active
- 2021-04-30 CA CA3177335A patent/CA3177335A1/en active Pending
- 2021-04-30 PL PL21722227.2T patent/PL4143179T3/pl unknown
- 2021-04-30 HR HRP20251578TT patent/HRP20251578T1/hr unknown
- 2021-04-30 JP JP2022564756A patent/JP7789693B2/ja active Active
- 2021-04-30 AU AU2021266148A patent/AU2021266148A1/en active Pending
-
2022
- 2022-10-26 IL IL297675A patent/IL297675B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4143179A1 (en) | 2023-03-08 |
| TWI904157B (zh) | 2025-11-11 |
| BR112022021976A2 (pt) | 2022-12-13 |
| US20230174514A1 (en) | 2023-06-08 |
| UA130467C2 (uk) | 2026-02-25 |
| IL297675A (en) | 2022-12-01 |
| JP7789693B2 (ja) | 2025-12-22 |
| MA59447B1 (fr) | 2025-12-31 |
| RS67648B1 (sr) | 2026-02-27 |
| WO2021219849A1 (en) | 2021-11-04 |
| JP2023523300A (ja) | 2023-06-02 |
| CA3177335A1 (en) | 2021-11-04 |
| PH12022500015A1 (en) | 2023-09-11 |
| HRP20251578T1 (hr) | 2026-01-30 |
| ES3055903T3 (en) | 2026-02-16 |
| AU2021266148A1 (en) | 2023-01-05 |
| AR121982A1 (es) | 2022-07-27 |
| EP4143179C0 (en) | 2025-10-22 |
| IL297675B1 (en) | 2026-03-01 |
| KR20230005938A (ko) | 2023-01-10 |
| EP4143179B1 (en) | 2025-10-22 |
| TW202200560A (zh) | 2022-01-01 |
| CN115551841A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4143179T3 (pl) | Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworu | |
| EP3849549A4 (en) | POLYTHERAPY FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER | |
| EP3781564A4 (en) | Compounds for the treatment of cancer | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL304595A (en) | Bicyclic tetrahydrozepine derivatives for cancer treatment | |
| IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
| IL307338A (en) | Pyridinyl substituted oxisoisoindoline compounds for cancer therapy | |
| EP3860610A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| EP3813854A4 (en) | IN VIVO REGULATED POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| IL305780A (en) | Cancer treatment methods | |
| EP4157246B8 (en) | Therapeutic combination for the treatment of breast cancer | |
| EP3856784A4 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | |
| HK40089330B (zh) | 用於癌症治疗的作为ccr6受体调节剂的氮杂环丁烷-3-基甲醇衍生物 | |
| HK40089330A (zh) | 用於癌症治疗的作为ccr6受体调节剂的氮杂环丁烷-3-基甲醇衍生物 | |
| SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
| HK40114414A (en) | Dr5-targeting multabodies for the treatment of cancer | |
| HK40082904A (en) | Therapy for the treatment of cancer | |
| IL315444A (en) | Expression system for cancer treatment | |
| HK40080165A (en) | Therapy for the treatment of cancer |